PetVivo Inc.
(PETVW)
undefined
undefined%
At close: undefined
Company Description
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals.
Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses.
The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications.
PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
PetVivo Inc.
| Country | United States |
| IPO Date | Aug 11, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 20 |
| CEO | John Lai |
Contact Details
Address: 5251 Edina Industrial Boulevard Minneapolis, Minnesota United States | |
| Website | http://www.petvivo.com |
Stock Details
| Ticker Symbol | PETVW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001512922 |
| CUSIP Number | 716817119 |
| ISIN Number | US7168171194 |
| Employer ID | 99-0363559 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John Lai | Chief Executive Officer, President & Director |
| Garry N. Lowenthal | Chief Financial Officer |
| Randall A. Meyer | Chief Operating Officer |
| April Boyce | Vice President of Marketing |
| Bryan Monninger | Vice President of Sales |
| Gary DeMel | Executive Vice President of Business Development |
| John F. Dolan | General Counsel, Chief Business Development Officer & Secretary |
| Randy Wenthold | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | PRER14C | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |